Genome‐wide association studies of exacerbations in children using long‐acting beta2‐agonists

Abstract excerpt

BACKGROUND: Some children with asthma experience exacerbations despite long-acting beta2-agonist (LABA) treatment. While this variability is partly caused by genetic variation, no genome-wide study until now has investigated which genetic factors associated with risk of exacerbations despite LABA use in children with asthma. We aimed to assess whether genetic variation was associated with exacerbations in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Asthma and respiratory diseases
• Share to Genetic Associations and Epidemiology
• Share to Pharmacogenetics and Drug Metabolism